ArticleBMC health services research2022

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis.

Mehdi Rezaee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.